Lonza LONN.SW stock CHF 553.60 before Q4 28 Jan 2026: guidance will set trend
Lonza Group AG (LONN.SW) trades at CHF 553.60 intraday on the SIX in Switzerland as the market awaits Q4 results on 28 Jan 2026. The upcoming announcement will centre on guidance and margins, and the stock is trading between a day low CHF 542.40 and day high CHF 585.60. Investors watch earnings for signs the Biologics and Cell & Gene segments are outpacing cost pressure. Our earnings spotlight connects reported metrics to price action and short-term outlook for LONN.SW stock ahead of the call.
LONN.SW stock: Earnings timing and what analysts will watch
Lonza reports Q4 results on 28 Jan 2026 with an earnings release and conference call scheduled after markets. Analysts will focus on revenue mix, margin trajectory and any forward-looking client cadence in biologics contracts. We expect commentary on capacity utilization, contract ramp timing and margin guidance. With trailing EPS 10.38 and PE 53.80, management guidance matters for multiple quarters of valuation.
LONN.SW stock: Division-level drivers and near-term growth
Lonza’s key drivers are Biologics, Small Molecules, Cell & Gene, and Capsules and Health Ingredients. Biologics and Cell & Gene typically drive higher-margin growth and are sensitive to client project timing. We will watch backlog commentary, new client wins, and CDMO pricing trends. Any positive Q4 beat in Biologics could support a short-term re-rating of LONN.SW stock.
LONN.SW stock: Financials, valuation and sector context
Lonza shows mixed fundamentals: operating cash flow per share 16.59 but free cash flow per share -3.80, and dividend per share 4.00. Valuation remains rich versus the Swiss healthcare sector average PE 34.64, while Lonza’s PE is 53.46. Key ratios: price-to-sales 5.52, price-to-book 4.55, debt-to-equity 0.54, and net debt to EBITDA 2.10. These figures explain why traders treat earnings guidance as a catalyst for LONN.SW stock revaluation.
LONN.SW stock: Intraday technicals and trading flow
Intraday price sits at CHF 553.60 after opening CHF 571.80; volume is 167,655 versus avg 133,173, showing higher participation. RSI is 51.12, MACD histogram 1.32, and ADX 25.79 indicating a trend environment. Short-term support aligns with the 50-day average CHF 541.64 and resistance near the 200-day average CHF 555.32 and the year high CHF 616.00. Watch volatility; ATR is 10.35.
LONN.SW stock: Risks, catalysts and market reaction scenarios
Primary risks include a disappointing guidance cut, customer concentration, and extended free cash flow weakness. A weaker-than-expected Biologics cadence could push the stock lower given the high PE. Catalysts include stronger backlog disclosure, improved utilization, and higher margin guidance. Intraday, any beat-plus-upgrade combination could trigger a quick 3.0 to 6.0 percent move in LONN.SW stock.
LONN.SW stock: Meyka AI grade and price forecast
Meyka AI rates LONN.SW with a score out of 100: 68.10 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly CHF 559.70 and quarterly CHF 573.40 versus the current CHF 553.60, implying a short-term upside of +1.10% and +3.58% respectively. The 1-year model price is CHF 477.32, implying -13.78%. Forecasts are model-based projections and not guarantees. For related market context see coverage on Investing.com stock news and broader SIX listings at Investing.com equities. For a quick stock page see Lonza LONN.SW on Meyka.
Final Thoughts
Key takeaways for LONN.SW stock on 28 Jan 2026: Lonza trades at CHF 553.60 intraday ahead of a Q4 report that will centre on guidance and margin outlook. Valuation is rich with PE 53.80, so the market will reward clear, sustainable margin improvement. Meyka AI rates LONN.SW with 68.10 out of 100 (Grade B, HOLD), reflecting solid fundamentals but stretched multiples versus the healthcare sector. Our short-term model sees modest upside: monthly forecast CHF 559.70 (+1.10%). The 1-year view is more conservative at CHF 477.32 (-13.78%). Traders should watch management guidance and Biologics backlog. These items will determine whether LONN.SW stock corrects lower or re-rates higher once earnings are digested. Meyka AI provides this AI-powered market analysis platform insight to help frame the risk-reward before the call. Remember forecasts are projections and not guarantees.
FAQs
When does Lonza report earnings and how might it move LONN.SW stock?
Lonza reports Q4 results on 28 Jan 2026. A positive revenue or margin surprise and stronger guidance typically lifts LONN.SW stock by several percent, while a cautious outlook could trigger a larger pullback.
What valuation metrics matter most for LONN.SW stock?
PE 53.80, price-to-sales 5.52, and free cash flow per share -3.80 are key. Investors compare these to sector averages and focus on guidance that justifies a premium valuation for LONN.SW stock.
How does Meyka AI view LONN.SW stock near earnings?
Meyka AI rates LONN.SW 68.10/100 (B, HOLD) and models a near-term price CHF 559.70 (+1.10%). The grade factors sector, growth and analyst consensus. Forecasts are model-based and not investment advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
